Background {#Sec1}
==========

*Escherichia coli* is an important cause of extra-intestinal infections, enteric disease, and systemic infections in humans and animals. Uropathogenic *Escherichia coli* (UPEC), one of the members of the extra-intestinal pathogenic *E. coli* (ExPEC) is a predominant pathogen causing urinary tract infections (UTIs) \[[@CR1]\]. UPEC is one of the main causes of community (80--90%) and nosocomial-acquired UTIs (30--50%) \[[@CR2]\]. These strains harbor a variety of virulence factors that allow them to establish an infection, including adhesins, toxins, host defense avoidance mechanisms and multiple iron acquisition systems \[[@CR3]\].

UTIs are one of the most common bacterial infections worldwide. It has been estimated that 150 million UTIs occur per year worldwide \[[@CR4]\]. ExPEC strains are responsible for an estimated 40,000 deaths and at least \$2.6 billion of expenses in healthcare treatment in the United States alone \[[@CR5]\]. In Mexico, 3'648,784 cases were reported on 2015 \[[@CR6]\]. Although these infections are treatable, the increasingly accelerated rates or multi-drug resistant organisms (MDRO) lead to complication, treatment failure and increased rates of mortality and morbidity \[[@CR7]\].

The enhanced prevalence and global spread of extended-spectrum beta-lactamase (ESBL) genes \[[@CR8]\] such as CTX-M enzymes that are associated to multidrug-resistant (MDR) phenotypes and fluoroquinolones resistance, has become a major concern \[[@CR9], [@CR10]\]. Quinolones are broad-spectrum antibiotics and very important in the treatment of a wide range of diseases, especially urinary tract infections. Quinolone resistance is mainly caused by chromosomal mutations in the quinolone resistance-determining region (QRDR) of gyrase (*gyrA* and *gyrB*) and topoisomerase (*parC* and *parE*) genes, but also is caused by plasmid-mediated quinolone resistance (PMQR) which include: the pentapeptide repeat family Qnr proteins (QnrA, QnrB, QnrS, QnrC and QnrD) \[[@CR11]\], the variant of the aminoglycoside-acetyltransferase modifying enzyme, AAC(6′)-lb-cr \[[@CR12]\], and the efflux pumps QepA and OqxAB \[[@CR13]--[@CR15]\]. Although PMQR genes confer only low-level of resistance to quinolones \[[@CR16]\] they could spread horizontally among *Enterobacteria* and facilitate the selection of resistant mutants as well as the selection of additional resistance mechanisms, enabling bacteria to become fully resistant \[[@CR8], [@CR17]\].

The emergence of MDR *E. coli* causing urinary tract infections with high virulence potential is alarming. In Mexico, a high rate of resistance against quinolones has been observed in environmental, diarrheagenic \[[@CR18]\], and pediatric clinical isolates \[[@CR19]\]. MDR phenotype of UPEC has also been shown \[[@CR20], [@CR21]\]. However, lack of sufficient data on virulence spectrum and MDR-UPEC isolates from community and hospital infections hinders the infections control and management efforts. The aim of this study was to determine the occurrence of MDR-phenotype, antibiotic resistance profile, virulence traits, and genetic background of *E*. *coli* isolates from community and hospital-acquired UTIs from Mexico.

Methods {#Sec2}
=======

*Escherichia coli* isolation {#Sec3}
----------------------------

This study was conducted on a total of one hundred and ten urine cultures collected from patients suspected to have an UTI (urine samples contained bacterial counts to ≥ 10^5^ CFU/ml) and sought attention in the Centenario Hospital Miguel Hidalgo, in Aguascalientes, Mexico during the period June to November 2012. Patient's ages ranged from neonatal to 91 years. Only one non-duplicated *E. coli* isolate per culture was considered. Patients from whom *E. coli* was isolated at least 48 h after admission were considered to have a hospital-acquired infection, all other infections were considered to be community-acquired \[[@CR22]\]. To isolate *E. coli*, serial decimal dilutions of the sample were prepared in 0.85% NaCl, and were used to inoculate MacConkey agar plates which were incubated overnight at 37 °C. All the isolates were screened by PCR for the *uidA* gene as confirmation (Table [1](#Tab1){ref-type="table"}). The *E. coli* isolates were stored at − 80 °C in Luria--Bertani broth and 20% (vol/vol) glycerol.Table 1Oligonucleotides used in this studyOligonucleotide nameTarget geneOligonucleotide 5′ ➔ 3′Amplification product (bp)References*E. coli* marker uidA-forward*uidA*ATGTGCTGTGCCTGAACC450\[[@CR60]\] uidA-reverseATTGTTTGCCTCCCTGCTGVirulence genes for extra-intestinal pathogenic *E. coli* papC-forward*papC*GACGGCTGTACTGCAGGGTGTGGCG350\[[@CR61]\] papC-reverseATATCCTTTCTGCAGGGATGCAATA SfaSf*sfaS*GTGGATACGACGATTACTGTG240\[[@CR62]\] SfaSrCCGCCAGCATTCCCTGTATTC Afaf*afa/dra*GGCAGAGGGCCGGCAACAGGC592\[[@CR62]\] AfarCCCGTAACGCGCCAGCATCTC FyuAf*fyuA*TGATTAACCCCGCGACGGGAA880\[[@CR62]\] FyuArCGCAGTAGGCACGATGTTGTA yfcV-forward*yfcV*ACATGGAGACCACGTTCACC292\[[@CR63]\] yfcV-reverseGTAATCTGGAATGTGGTCAGG Vat-forward*vat*TCAGGACACGTTCAGGCATTCAGT1100\[[@CR63]\] Vat-reverseGGCCAGAACATTTGCTCCCTTGTT KpsMIIf*kpsMT II*GCGCATTTGCTGATACTGTTG272\[[@CR62]\] KpsMIIrCATCCAGACGATAAGCATGAGCAQuinolone resistance genes gyrA11753*gyrA*GTATAACGCATTGCCGC251\[[@CR64]\] gyrA12004TGCCAGATGTCCGAGAT EC-PAR-A*parC*CTGAATGCCAGCGCCAAATT189\[[@CR65]\] EC-PAR-BGCGAACGATTTCGGATCGTC qnrA-forward*qnrA*TCAGCAAGAGGATTTCTCA605\[[@CR66]\] qnrA-reverseGGCAGCACTATTACTCCCA qnrB-forward*qnrB*GATCGTGAAAGCCAGAAAGG469\[[@CR12]\] qnrB-reverseACGATGCCTGGTAGTTGTCC qnrS-forward*qnrS*ACGACATTCGTCAACTGCAA417\[[@CR12]\] qnrS-reverseTAAATTGGCACCCTGTAGGC qnrC-forward*qnrC*GGGTTGTACATTTATTGAATC447\[[@CR64]\] qnrC-reverseTCCACTTTACGAGGTTCT qnrD-forward*qnrD*CGAGATCAATTTACGGGGAATA582\[[@CR27]\] qnrD-reverseAACAAGCTGAAGCGCCTG qepA-forward*qepA*CTGCAGGTACTGCGTCATG403\[[@CR67]\] qepA-reverseCGTGTTGCTGGAGTTCTTC aac-forward*acc*-*(6′)*-*lb*TTGCGATGCTCTATGAGTGGCTA482\[[@CR26]\] aac-reverseCTCGAATGCCTGGCGTGTTTBeta-lactamase resistant genes blaTEM-forward*bla* ~TEM~GAGTATTCAACATTTTCGT857\[[@CR30]\] blaTEM-reverseACCAATGCTTAATCAGTGA blaSHV-forward*bla* ~SHV~TCGCCTGTGTATTATCTCCC768\[[@CR30]\] blaSHV-reverseCGCAGATAAATCACCACAATG blaOXA-1-forward*bla* ~OXA-1~GCAGCGCCAGTGCATCAAC198\[[@CR30]\] blaOXA-1-reverseCCGCATCAAATGCCATAAGTG blaOXA-7-forward*bla* ~OXA-7,\ -9~AGTTCTCTGCCGAAGCC591\[[@CR30]\] blaOXA-7-reverseTCTCAACCCAACCAACCC blaPSE-4-forward*bla* ~PSE-4~CTGCTCGTATAGGTGTTTCC705\[[@CR30]\] blaPSE-4-reverseTCGCATCATTTCGCTCTTC blaCTX-M-3-f*bla* ~CTX-M-3~AATCACTGCGTCAGTTCAC701\[[@CR30]\] blaCTX-M-3-rTTTATCCCCCACAACCCAG blaCTX-M-forward*bla* ~CTX-M~AAGGCGTTTTGACAGACTATT920This study blaCTX-M-reverseGGTGACGATTTTAGCCGC

Antimicrobial susceptibility test {#Sec4}
---------------------------------

Susceptibility to antimicrobial agents was determined by the agar dilution method as recommended by the standards of Clinical Laboratory Standards Institute \[[@CR23]\]. The following antimicrobial agents were tested: ampicillin, ampicillin--sulbactam, amoxicillin--clavulanic acid, piperacillin--tazobactam, cefazolin, cefotaxime, ceftazidime, ceftriaxone, cefepime, amikacin, gentamicin, tobramycin, netilmicin, imipenem, ertapenem, trimethoprim--sulfamethoxazole, ciprofloxacin, levofloxacin and norfloxacin. *E. coli* ATCC 25922 was included in each assay as a negative control.

Determination of phylo-groups {#Sec5}
-----------------------------

Phylo-grouping was determined by PCR as previously described by Clermont et al. \[[@CR24]\]. *E. coli* strains H10407 (phylo-group A), E22 (phylo-group B1), CFT073 (phylo-group B2), ECOR 70 (phylo-group C), O42 (phylo-group D), EDL933 (phylo-group E) and ECOR 36 (phylo-group F), were taken as positive controls. Water was used as negative control. All strains controls were kindly provided by Laboratoire de référence pour *Escherichia coli*, EcL, Faculté de Médecine Vétérinaire, Université de Montréal.

Detection of virulence factors {#Sec6}
------------------------------

*Escherichia coli* isolates from urinary tract infections were screened for the presence of commonly detected UPEC virulence genes including: *fyuA*, *fimH*, *sfaS*, *afa/dra*, *papC*, *agn43, yfcV*, *vat*, *hlyA*, *cnf1*and *kpsMTII*. Primers and controls used in this study are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 2PCR control strains used in this studyControl strainPositive gene (s)J53pMG252*qnrA*J53pMG298*qnrB*J53pMG306*qnrSSalmonella* SA20042859*aac(6′)*-*Ib*CFT073*uidA, papC, fyuA, chuA, kpsMTII, yfcV*J96*sfaS*UTI89*vat*R455*bla* ~OXA-1~R6 K*bla* ~TEM~HB101*bla* ~SHV~pMG202*bla* ~OXA-7,\ -9~pMON711*bla* ~PSE-4~CCRI-2167*bla* ~CTX-M~

Characterization of resistance genes and mutations {#Sec7}
--------------------------------------------------

Screening for plasmid mediated quinolone resistance (PMQR) genes, including *qnrA*, *qnrB*, *qnrS*, *qnrC, qnrD*, *qepA*, and *acc(6′)*-*lb* genes was performed as previously described \[[@CR13], [@CR25]--[@CR28]\]. The *qnrC*, *qnrD* and *aac (6′)*-*Ib cr* variants were identified sequencing the PCR products. The quinolone resistance determining regions (QRDR) of *gyrA* and *parC* genes were amplified and sequenced on both strands and predicted peptide sequences were compared to the corresponding gene from the MG1655 genome as described by Namboodiri et al. \[[@CR29]\]. Beta-lactams genes detection including *bla*~TEM~, *bla*~SHV~, *bla*~OXA~, *bla*~PSE~ and *bla*~CTX-M~ were carried out by PCR amplification using specific primers \[[@CR30]\]. Amplicons from all of the *bla*~CTX-M~ positive isolates were sequenced. The nucleotide sequences obtained were aligned and further analyzed by comparison to sequences from a catalogue of beta-lactamases (<http://www.lahey.org/studies/>).

DNA microarray analysis {#Sec8}
-----------------------

Microarray hybridizations were performed using *E. coli* maxivirulence version 3.1 microarray as previously described \[[@CR31]\]. It allows the detection of 348 virulence genes and 98 antibiotic resistance genes and variants. DNA extraction and hybridizations were performed as described previously \[[@CR32]\]. Each isolate was assigned to a specific *E. coli* pathotype according to its virulence gene profile and based on the classification published in previous papers \[[@CR31], [@CR33]\].

Statistical analysis {#Sec9}
--------------------

Categorical variables were compared using Pearson's Chi square or Fisher's exact test as appropriate. Continuous variables were compared using Mann--Whitney U test (STATISTICA V. 10, StatSoft, United States). p values less than 0.05 were considered statistically significant.

Results {#Sec10}
=======

Patient demographics {#Sec11}
--------------------

During the period of study, females (86 samples, 78.2%) were the most affected group of patients (*p* \< 0.05) as compared to males (24 samples, 21.8%). Most of the UTIs were detected in community obtained samples (79 samples, 71.8%). Thirty-one samples were recovered from hospital-acquired infections (28.2%). *E. coli* isolated from female patients were correlated with community-acquired UTIs (*p* = 0.0297). No differences among the prevalence of *E. coli* isolated from male patients among community- and hospital-acquired infections were found (54.2% vs 45.8%, respectively). Maximum number of cases was found in female children in the age group of 2--10 years (34 samples, 39%, *p* = 0.0372, Table [3](#Tab3){ref-type="table"}).Table 3Patients with urinary tract infections, n (%)Age groupAll patients, *n *= 110 (%)Male, *n* = 24 (%)Female, *n* = 86 (%)*\*p*Hospital-acquired, *n* = 31 (%)Community-acquired, *n* = 79 (%)*\*p*0--117 (15.5)6 (25.0)11 (12.8)0.14345 (16.1)12 (15.2)0.90242--1038 (34.5)4 (16.7)34 (39.5)*0.0372*9 (29.0)29 (36.7)0.446211--2012 (10.9)1 (4.2)11 (12.8)0.23082 (6.5)10 (12.7)0.347521--307 (6.4)2 (8.3)5 (5.8)0.65481 (3.2)6 (7.6)0.398331--406 (5.5)1 (4.2)5 (5.8)0.75331 (3.2)5 (6.3)0.519141--505 (4.5)0 (0.0)5 (5.8)0.22661 (3.2)4 (5.1)0.677251--606 (5.5)2 (8.3)4 (4.7)0.48243 (9.7)3 (3.8)0.221861--707 (6.4)3 (12.5)4 (4.7)0.16363 (9.7)4 (5.1)0.3724\> 7112 (10.9)5 (20.8)7 (8.1)0.07776 (19.4)6 (7.6)0.0751\* Italic number shown statistical significant values

Antibiotic resistance and MDR profiles in *E. coli* isolates {#Sec12}
------------------------------------------------------------

High frequencies of resistance were observed toward trimethoprim--sulfamethoxazole (72.7%), ampicillin (70.9%), ampicillin--sulbactam (55.5%), piperacillin--tazobactam (55.5%), ciprofloxacin (47.3%), and levofloxacin (43.6%). From the twenty different antibiotic tested, all isolates were susceptible to carbapenems (ertapenem and imipenem, Table [4](#Tab4){ref-type="table"}). Eighty-seven percent of the isolates were resistant to at least one antimicrobial agent, and 63.3% (70 isolates) were multidrug-resistant (MDR). MDR isolates were resistant to ampicillin (85.7%), trimethoprim--sulfamethoxazole (84.3%), ampicillin--sulbactam (77.1%), piperacillin--tazobactam (77.1%) and ciprofloxacin (70%, Table [4](#Tab4){ref-type="table"}). A total of 94.2% (49/52 isolates) of FQ-resistant strains showed MDR-phenotype. A similar distribution of FQ-resistant isolates was found in the same at hospital as community-acquired infections, except for norfloxacin, which was higher among community-acquired infections (20.3% vs 6.5%, Table [4](#Tab4){ref-type="table"}). Distribution of ciprofloxacin and levofloxacin resistance was significantly higher among male than female gender (70.8, 66.7%, *p *= 0.0089, 0.0314 vs 40.7, 37.2%, respectively, Table [4](#Tab4){ref-type="table"}).Table 4Antibiotic and multidrug resistance of the UPEC's isolates, n (%)AntibioticsTotal isolates, *n* = 110 (%)MDR, *n* = 70 (%)Male, *n* = 24 (%)Female, *n* = 86 (%)*\*p*Hospital-acquired, *n* = 31 (%)Community-acquired, *n* = 79 (%)*\*p*Amikacin11 (10.0)11 (15.9)4 (16.7)7 (8.1)1 (3.2)10 (12.7)Gentamicin31 (28.2)29 (41.4)11 (45.8)20 (23.3)0.029710 (32.3)21 (26.6)Tobramycin21 (19.1)21 (30.0)10 (41.7)11 (12.8)0.00159 (29.0)12 (15.2)Netilmicin6 (5.5)5 (7.1)2 (8.3)4 (4.7)2 (6.5)4 (5.1)Ampicillin78 (70.9)60 (85.7)20 (83.3)58 (67.4)24 (77.4)54 (68.4)Ampicillin--sulbactam61 (55.5)54 (77.1)15 (62.5)46 (53.5)18 (58.1)43 (54.4)Amoxicillin--clavulanic acid26 (23.6)23 (32.9)5 (20.8)21 (24.4)6 (19.4)20 (25.3)Piperacillin--tazobactam61 (55.5)54 (77.1)15 (62.5)46 (53.5)18 (58.1)43 (54.4)Cefazolin46 (41.8)45 (64.3)15 (62.5)31 (36.0)0.020216 (51.6)30 (38.0)Cefotaxime20 (18.2)20 (28.6)5 (20.8)15 (17.4)6 (19.4)14 (17.7)Ceftazidime27 (24.5)27 (38.6)13 (54.2)14 (16.3)0.000112 (38.7)15 (19.0)0.0306Ceftriaxone30 (27.3)30 (42.9)14 (58.3)16 (18.6)0.000113 (41.9)17 (21.5)0.0305Cefepime29 (26.4)29 (41.4)14 (58.3)15 (17.4)0.000112 (38.7)17 (21.5)Trimethoprim--sulfamethoxazole80 (72.7)59 (84.3)18 (75.0)62 (72.1)24 (77.4)56 (70.9)Ciprofloxacin52 (47.3)49 (70.0)17 (70.8)35 (40.7)0.008915 (48.4)37 (46.8)Levofloxacin48 (43.6)45 (64.3)16 (66.7)32 (37.2)0.031413 (41.9)35 (44.3)Norfloxacin18 (16.4)18 (25.7)3 (12.5)15 (17.4)2 (6.5)16 (20.3)Nitrofurantoin14 (12.7)12 (17.1)5 (20.8)9 (10.5)4 (12.9)10 (12.7)0.0002Ertapenem0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Imipenem0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)\* Only statistical significant values are shown

Co-resistance phenotype between cephalosporins and beta-lactams towards fluoroquinolones was frequently observed \[(amoxicillin--clavulanic acid (*p* = 0.0004), cefazolin (*p* = 0.0299), cefotaxime (*p* = 0.0001), ceftriaxone (*p* = 0.0002) and, cefepime (*p* = 0.0015)\]. Trimethoprim--sulfamethoxazole and cephalosporins \[cefotaxime (*p* = 0.0232) and ceftazidime (*p* = 0.0001)\] also showed a co-resistance.

Overall, hospital-acquired isolates were slightly more resistant than community-acquired isolates (33.1% vs 28.7%, respectively). Both hospital and community-acquired isolates showed higher resistance towards ampicillin (77.4% vs 68.4%) and trimethoprim--sulfamethoxazole (77.4% vs 70.9%). UPEC isolates from hospital-acquired infections were associated to ceftazidime (*p* = 0.0306), ceftriaxone (*p* = 0.0305), and nitrofurantoin (*p* = 0.0002) resistance phenotype (Table [4](#Tab4){ref-type="table"}). MDR-phenotype was equally distributed among community-acquired (64.5%) and hospital-acquired (61.3%) isolates. Moreover, MDR-phenotype was associated to male infections (83.33%, *p* = 0.02329). MDR-phenotype (69.6%) as well as the FQ-resistant phenotype (69.6%, p = 0.0008) was also prevalent among older adults (\> 60 years old).

Phylogenetic characterization, virulence genes, and their association to MDR-phenotype {#Sec13}
--------------------------------------------------------------------------------------

All seven phylogenetic lineages (A, B1, B2, C, D, E and F) and cryptic clades were found on the 110 urinary *E*. *coli* isolates. The phylo-groups D (23.6%) and A (19.1%) were the most commonly found, followed by B1 (15.5%), C (13.6%), B2 (11.8%), F (10%), cryptic clades (5.5%) and phylo-group E (0.9%). The different phylo-groups and cryptic clades were distributed in both hospital and community settings, except the phylo-group E which was only distributed in the hospital-acquired infections. MDR strains were distributed into all phylogenetic-groups: 26% (16/70) to A, 17.1% (12/70) to D, 15.7% (11/70) to B1, 12.9% (9/70) to C, 11.4% (8/70) to B2 and F, and 6.7% (5/70) to cryptic clades. Phylo-group D was significantly associated to MDR-phenotype (*p* = 0.0339) as well as FQ-resistant phenotype (26%, *p* = 0.0173). Phylo-groups B2 and D were more common among community-acquired isolates (18.2, 9.1%) than hospital-acquired isolates (5.5, 2.7%), as well as in females (20.9, 7.3%) than in males (4.5, 2.7%) but not significantly associations were found.

Overall, *fimH* (71.8%), *fyuA* (68.2%), and *agn43* (54.5%) were the virulence genes with the highest distributions among isolates, while *afa/dra* (8.2%) and *cnf1* (2.7%) had the lowest. Others virulence genes tested had the following distribution: *chuA*, 49.1%; *papC*, 42.7%; *kpsMTII*, 37.3%; *vat*, 20%; *yfcV*, 20%; *sfaS* 10%, and *hlyA*, 9.1% (Table [5](#Tab5){ref-type="table"}). Isolates from hospital-acquired infections presented slightly more prevalence of virulence genes than community-acquired infections (35.2% vs 30.2%). Prevalence of *fyuA* (71.0% vs 67.1%), *papC* (48.4% vs 40.5%), *yfcV* (25.8% vs 55.7%), *hlyA* (12.9% vs 7.6%), *cnf1* (3.2% vs 2.5%), *kpsMTII* (58.1% vs 29.1%) and *chuA* (51.6% vs 48.1%) were higher among UPEC isolated from hospital-acquired than community-acquired infections. However, only the *kpsMTII* was significantly associated with hospital-acquired isolates (58.1% vs 29.1%, *p* = 0.0047, Table [5](#Tab5){ref-type="table"}). Comparing male vs female patients, isolates from females had a higher mean of virulence genes compared those isolates from male origin (21.5% vs 7.9%, respectively). Moreover, the *yfcV* was significantly more associated to male infections (41.7%, *p* = 0.0026). The presence of the *chuA* gene was associated to UPEC isolated from children (*p *= 0.0483). Furthermore, the presence of *vat* was associated to UPEC isolates from adults (*p *= 0.0153).Table 5Distribution of virulence genes among UPEC strains, n (%)Virulence genesTotal isolates, *n* = 110 (%)MDR, *n* = 70 (%)Male, *n* = 24 (%)Female, *n* = 86 (%)*\*p*Hospital-acquired, *n* = 31 (%)Community-acquired, *n* = 79 (%)*\*pfyuA*75 (68.2)46 (65.7)14 (58.3)61 (70.9)22 (71.0)53 (67.1)*fimH*79 (71.8)51 (72.9)20 (83.3)59 (68.6)21 (67.7)58 (73.4)*sfaS*11 (10)6 (8.6)2 (8.3)9 (10.5)2 (6.5)9 (11.4)*afa/dra*9 (8.2)5 (7.1)0 (0.0)9 (10.5)2 (6.5)7 (8.9)*papC*47 (42.7)27 (38.6)12 (50.0)35 (40.7)15 (48.4)32 (40.5)*agn43*60 (54.5)39 (55.7)14 (58.3)46 (53.5)16 (51.6)44 (55.7)*yfcV*22 (20)15 (21.4)10 (41.7)12 (14.0)0.00268 (25.8)14 (17.7)*vat*22 (20)13 (18.3)7 (29.2)15 (17.4)6 (19.4)16 (20.3)*hlyA*10 (9.1)7 (10.0)4 (16.7)6 (7.0)4 (12.9)6 (7.6)*cnf1*3 (2.7)2 (2.9)1 (4.2)2 (2.3)1 (3.2)2 (2.5)*kpsMTII*41 (37.3)25 (35.7)9 (37.5)32 (37.2)18 (58.1)23 (29.1)0.0047*chuA*54 (49.1)32 (45.7)11 (45.8)43 (50.0)16 (51.6)38 (48.1)\* Only statistical significant values are shown

Virulence genes *fimH* (72.9%), *fyuA* (65.7%), *agn43* (55.7%) and *chuA* (45.7%, Table [5](#Tab5){ref-type="table"}), were highly distributed among MDR strains. However none virulence genes were significantly associated to MDR-phenotype or FQ-resistant isolates. Nevertheless, *fimH* (69.2%), *fyuA* (67.3%) and *chuA* (57.7%) were highly distributed among FQ-resistant bacteria.

Identification of virulence, and antimicrobial resistance genes by microarray analysis {#Sec14}
--------------------------------------------------------------------------------------

Microarray analysis was done on 18 *E. coli* isolates belonging to the phylo-groups B2, D and F. Overall, 145 virulence and 40 antimicrobial resistance genes among the 315 and 82 genes and variants investigated were detected at least once in one or more of the isolates. The total number of virulence genes per isolate ranged from 18 to 63 genes. The median number of the virulence genes per isolate was 35. Microarray hybridizations demonstrated that all the *E. coli* isolates tested possessed virulence genes related to a pathotype including ExPEC and diarrheagenic *E*. *coli* (DEC). The total number of antimicrobial resistance genes per isolate ranged from 0 to 21 genes with a median number of 6.5 genes. Since the microarray carries a large set of virulence factors, numerous incomplete ExPEC that would normally be missed in a PCR-based assay were found. Thus, various unusual gene combinations were discovered, such as ExPEC pathogenic profiles with assorted EPEC genes coding for the type III secretion system 2 proteins ErpJ and SpaS (gene *eprJ* and *epaS*, respectively). Moreover, detection of virulence (mean 39.0 ± 16.9) and antimicrobial resistance (mean 9.0 ± 1.9) genes were higher on hospital-acquired UTIs isolates compared to community-acquired infections (Table [6](#Tab6){ref-type="table"}). Higher frequency of virulence genes was found among isolates retrieved from females compared to those from males (36.25 ± 17.04 mean vs 31.66 ± 13.00 mean, respectively), as well as those isolates from children vs adults (36.58 ± 7.4 mean vs 26.6 ± 16.39 mean, respectively). In addition, antimicrobial resistance genes were also detected on higher ratios among isolates retrieved from males compared to those from females (7.88 ± 5.53 mean vs 4.0 ± 3.03 mean, respectively); a similar situation was observed when strains isolates from children vs those from adults were compared (14.60 ± 5.79 mean vs 4.4 ± 2.60 mean, respectively). Interestingly, the maximum number of antimicrobial resistance genes was found among UPEC isolates from children.Table 6Virulence and antimicrobial resistance genes detected by microarray analysis exclusively among *E. coli* B2, D and F isolates from UTIs patientsType of infectionHospital-acquired (*n *= 4)Community-acquired (*n *= 14)Virulence genes (mean)3932Antimicrobial resistance genes (mean)96Phylo-groupsB2 (*n* = 2) and D (*n* = 2)B2 (*n* = 9), D (*n* = 3) and F (*n* = 2)Virulence genes function Resistance*bla*~TEM~, *bla*~OXA-1~, *bla*~PSE-1~, *bla*~CTX-M-15~, *bla*~CMY-2~, *mphA*, *ant(3″)*-*Ia (aadA1)*, *aac(3)*-*IIa (aacC2)*, *tet(A)*, *tet(B)*, *tet(30)*, *tet(R), sulI sulII*, *qnrA*, *aac(6′)*-*Ib*-*cr*, class 1 integron*bla*~TEM~, *bla*~OXA-1~, *bla*~OXA-9~, *bla*~PSE-1~, *bla*~CTX-M-15~, *bla*~CTX-M-12~, *bla*~OXY/K1~, *ant(3″)*-*Ia (aadA1)*, *aac(3)*-*IIa (aacC2)*, *aac(3)*-*IV*, *aph(3′)*-*Ia (aphA1)*, *aph(3′)*-*IIa (aphA2)*, *aph3 (strA)*, *dhfrI*, *dhfrVII*, *catI*, *sulI*, *sulII*, *tet(A)*, *tet(B)*, *tet(30)*, *mphA*, class 1 integron, class 2 integron Adhesins*afaD*, *afaD8*, *afaE1*, *afaE2*, *afaE5*, *bfpA*, *fimC*, *ibeB*, *csgA*, *csgE*, *f165(1)A*, *fimA*, *fimH*, *iha*, *lpfA*(*O113*), *papA(10)*, *papA(11)*, *papA(16)*, *papA(8)*, *papC*, *papGI2*, *fitA*, *sfaHII*, *sfaDafaE1*, *afaE2*, *afaE5*, *cofA*, *lpfA2*, *fimC*, *csgA*, *csgE*, *csuA*, *F17b*-*A*, *F17d*-*A*, *facA*, *lpfA1*, *fimA*, *iha*, *lpfA(O113)*, *lpfA*, *papA(8)*, *papA(9)*, *papA(10)*, *papA(12)*, *papA(13)*, *papA(15)*, *papA(40)*, *papA(48)*, *papC*, *papGII*, *papGIV*, *fitA*, *sfaHII, sfaA* Colcins and microsins*cvaC*, *mchBcda*, *ce1a*, *cib*, *cvaC*, *mcbA*. Toxins*SatastA*, *astA(2)*, *cdtB*-*4*, *cnf1*, *sat* Iron acquisition or transport system*chuA*, *fepC*, *fyuA*, *iroN*, *iroN(2)*, *irp1*, *irp2*, *iucD*, *iutA*, *iutA(2)*, *iutA(UPEC)*, *sitA*, *sitDchuA*, *fepC*, *fimH*, *fyuA*, *iroN(2)*, *irp1*, *irp2*, *iucD*, *iutA*, *iutA(2)*, *iutA(UPEC)*, *sitA*, *sitD* Capsular and somatic antigens*kpsMTII*, *neuCkpsMTII*, *neuA, neuC* Locus of enterocyte effacement (LEE)*eae(delta)eae(lambda)*, *espG*, *esta1* ETT2 elements*eivG*, *eprJeivG*, *eprJ*, *epaS* Haemolysins and hemagglutinins*hlyA*, *hlyE*, *hra1bmaE*, *hlyA*, *hlyE*, *hra1*. Various functions*agn43*, *capU*, *ccdB*, *deoK*, *fliC*, *gad*, *iss*, *iss(3)*, *malX*, *ompA*, *ompT*, *ompT(2)*, *senB*, *traTagn43*, *capU*, *ccdB*, *ibeA*, *ibeB*, *deoK*, *eaf*, *fliC*, *fliC(H7)*, *gad*, *invX*, *iss*, *iss(3)*, *malX*, *ompA*, *ompT*, *ompT(2)*, *senB*, *traT* Newly recognized or putative *E. coli* virulence genes*artJ*, *b1121*, *b1432*, *gimB(orf1), mviM*, *mviN*, *shf*, *usp*, *virKartJ*, *b1121*, *mviM*, *mviN*, *set*, *shf*, *usp*, *virK*

Distribution of plasmid-mediated quinolone resistance genes, and ESBL genes {#Sec15}
---------------------------------------------------------------------------

Overall, 22% of the isolates were positive for *qnrA* (25 isolates), 20.9% (23 isolates) to *qnrB*, 6.4% (7 isolates) to *qnrS1*, 0.9% (1 isolates) to *qnrC*, 4.5% (5 isolates) to *qnrD*, and 6.4% (7 isolates) to *aac(6′)*-*Ib*-*cr* (Table [7](#Tab7){ref-type="table"}). None isolates were positive to *qepA* gene. Isolates were taken to sequencing to obtain information on the QRDRs of the *gyrA* and *parC* genes, respectively. The sequencing results for the QRDR of *gyrA* and *parC* are summarized in Table [8](#Tab8){ref-type="table"}. Only one isolate tested had no mutations in the QRDRs of *gyrA* and *parC* since was sensitive to ciprofloxacin (CIP), levofloxacin (LEV), and norfloxacin (NOR). The double mutations in Ser-83 → Leu and Asp-87 → Tyr or Asp-87 → Asn substitution in *gyrA* were present in 92% of the strain tested. Ser-80 → Ile substitution in *parC* were found in 92% of the isolates tested, which also were resistant to both ciprofloxacin and levofloxacin. The substitution Thr-66 → Ser (1 strain, CIP-resistant, LEV-resistant), Thr-66 → Asn (1 strain, CIP-resistant, LEV-resistant), and Thr-66 → Tyr (2 strains, CIP-resistant, LEV-resistant) were also found in *parC*. Other substitutions in *parC* as Glu-84 → Val (2 strains, CIP-resistant, LEV-resistant) and Glu-84 → Ala were also detected. Interestingly, one strain (isolated UEc 76) which was resistant to ciprofloxacin, levofloxacin and norfloxacin, belonging to B2 phylo-group and blaCTX-M-containing, also carried the double mutations in Ser-83 → Leu and Asp-87 → Asn substitution in *gyrA* and the triple mutation in *parC* Ser-80 → Ile, Thr-66 → Tyr and Glu-84 → Val.Table 7Distributions of PMQR and blaCTX-M genes among UPEC, n (%)Virulence genesTotal isolates, *n* = 110 (%)MDR, *n* = 70 (%)Male, *n* = 24 (%)Female, *n* = 86 (%)\**p*Hospital-acquired, *n* = 31 (%)Community-acquired, *n* = 79 (%)*qnrA*25 (22.7)15 (21.4)7 (29.2)18 (20.9)9 (29.0)16 (20.3)*qnrB*23 (20.9)13 (18.6)6 (25.0)17 (19.8)10 (32.3)13 (16.5)*qnrS*7 (6.4)3 (4.3)3 (12.5)4 (4.7)2 (6.5)5 (6.3)*qnrC*1 (0.9)0 (0.0)0 (0.0)1 (1.2)0 (0.0)1 (1.3)*qnrD*5 (4.5)4 (5.7)1 (4.2)4 (4.7)3 (9.7)2 (2.5)*aac(6′)*-*Ib*-*cr*7 (6.4)4 (5.7)4 (16.6)3 (3.5)0.01942 (6.5)5 (6.3)*bla* ~CTX-M~14 (12.4)11 (15.7)5 (20.8)9 (10.5)4 (12.9)10 (12.7)\* Only statistical significant values are shown Table 8Characterization of UTI isolatesStrainResistance profilePhylo-groupPMQR genesQRDR mutationsβ-lactamase-resistance-genesOther resistant genesIntegron**∆GyrA**∆ParCUEc 11AMP, SXTB2NANA*bla* ~TEM~*ant(3″)*-*Ia (aadA1)*, *aph3 (strA)*, *dhfrI*, *sulII*, *tet(B)*Class 2 integronUEc 22AMP, SAM, AMC, CFZ, SXT, CIP, LEV, NORB2S83 → L\
D87 → NS80 → I\
T66 → N*bla* ~TEM~*tet(B)*UEc 23AMP, SAM, CFZ, CTZ, CAZ, CRO, FEP, SXT, CIP, LEVF*aac(6′)*-*Ib*-*cr*NANA*aac(3)*-*IIa (aacC2)*Class 1 integronUEc 27GEN, AMP, SAM, AMC, SXT, CIP, LEVB2S83 → L\
D87 → NS80 → I\
E84 → V*bla* ~PSE-1~*sulI*, *tet(A)*UEc 30GEN, SAM, AMC, SXTB2NANA*bla* ~OXA-1~*ant(3″)*-*Ia (aadA1)*, *tet(A)*, *tet(30)*, *tet*^*®*^*, sulI*Class 1 integronUEc 58AMP, SXT, CIP, LEVB2S83 → L\
D87 → N\
G114 → SS80 → I*bla* ~TEM~*dhfrVII*, *sulII*, *tet(B)*, *aph3 (strA)*, *mphA*UEc 65AMP, CFZ, CAZ, CRO, FEP, CIP, LEVDS83 → L\
D87 → N\
G114 → SS80 → I*bla* ~CTX-M-15~\
*bla* ~TEM~*aac(3)*-*IIa (aacC2)*, *dhfrVII*, *mphA*, *sulI*, *tet(B)*Class 1 integronUEc 69AMP, SXT, NITB2*qnrA*NANA*bla* ~TEM~*sulII*UEc 75AMK, GEN, AMP, SAM, AMC, TZP, CFZ, CTX, CRO, FEPCIP, LEV, NORB2*qnrA*S83 → L\
D87 → NS80 → I\
T66 → Y*bla*~OXY/K1~, *bla*~TEM~*aac(3)*-*IIa (aacC2)*, *aph(3′)*-*Ia (aphA1)*, *aph(3′)*-*IIa (aphA2)*, *aph3 (strA)*, *sulI*, *sulII*, *tet(A)*, *tet(B)*UEc 76CFZ, CAZ, CRO, FEP, CIP, LEVB2S83 → L\
D87 → NS80 → I\
T66 → Y\
E84 → V*bla* ~CTX-M-15~\
*bla* ~OXA-1~*tet(A)*, *tet(30)*UEc 84GEN, TOB, AMP, SAM, TZP, CFZ, CTX, CAZ, CRO, FEP, SXT, CIP, LEVD*aac(6′)*-*Ib*-*cr*S83 → L\
D87 → NS80 → I*bla*~CTX-M-15~, *bla*~OXA-1~\
*bla* ~TEM~\
*bla* ~PSE-4~*tet(30)*, *mphA*UEc 99AMP, SXTB2*qnrA*NoneNone*bla*~CTX-M-12~,\
*bla*~OXA-9~, *bla*~TEM~*aac(3)*-*IV*, *aac(3)*-*IIa (aacC2)*, *aph3 (strA)*, *catI*, *sulI*, *sulII*Class 1 integronUEc 102AMP, CFZ, CAZ, CRO, FEP, SXT, CIP, LEVB2S83 → L\
D87 → N\
G114 → SS80 → I*bla* ~TEM~*aph(3′)*-*Ia (aphA1)*, *sulII*UEc 104AMP, SXTD*qnrA, aac(6′)*-*Ib*-*cr*NANA*bla*~CMY-2~,\
*bla*~CTX-M-12~, *bla*~OXA-1~*aac(3)*-*IIa (aacC2)*, *sulI*, *tet(B)*, *mphA*Class 1 integronUEc 107FNANAUEc 108AMPD*qnrA*NANA*bla* ~TEM~*sulI*Class 1 integronUEc 109AMP, SAMD*aac(6′)*-*Ib*-*cr*NANA*bla* ~TEM~*sulII*UEc 110GEN, TOB, AMP, SAM, CTX, SXT, CIP, NITB2NANA*aac(3)*-*IIa (aacC2)*, *tet(B)*Class 1 integron*AMK* Amikacin, *GEN* gentamicin, *TOB* tobramycin, *NET* netilmicin, *AMP* ampicillin, *SAM* ampicillin--sulbactam, *AMC* amoxicillin--clavulanic acid, *TZP* piperacillin--tazobactam, *CFZ* cefazolin, *CTX* cefotaxime, *CAZ* ceftazidime, *CRO* ceftriaxone, *FEP* cefepime; *SXT* trimethoprim--sulfamethoxazole, *CIP* ciprofloxacin, *LEV* levofloxacin, *NOR* norfloxacin, *NIT* nitrofurantoin, *ETP* ertapenem, *IPM* imipenem, *PMQR* plasmid-mediated quinolone resistance genes, *QRDR* quinolone resistance-determining region, *NA* not analyzed

ESBL genes were investigated through microarray and PCR assay. A total of 27 isolates (24.5%) suspected as cephalosporinase producers showed positive PCRs for *bla*~CTX-M~ (12.7%/14 isolates), *bla*~TEM~ (18.2%/20 isoaltes), *bla*~PSE~ (2.7%/3 isoaltes), and *bla*~OXA~ (9.1%/10 isolates). Sequencing of the *bla*~CTX-M~ amplicons identified the presence of *bla*~CTX-M-15~ in 7.2% of the strains (8 isolates), *bla*~CTX-M-12~ in 4.5% (5 isolates), *bla*~CTX-M-3~ in 1.8% (2 isolates), and *bla*~CTX-M-14~ in 1.8% (2 isolates). Furthermore, *bla*~ROB-1,~ *bla*~SHV-37~, and *bla*~CMY-2~ genes, were identified in one isolate (0.9%) through the microarray assay.

Overall *bla*~CTX-M~ genes and PMQR genes as well as mutation in QRDR were found in both community- and hospital-acquired infections as well as in male and female genders. The PMQR *qnrA* (21.4%), and *qnrB* (18.6%), were highly distributed on MDR-phenotype (Table [7](#Tab7){ref-type="table"}). Isolates from males had higher prevalence of *aac(6′)*-*Ib*-cr gene compare to female isolates (16.6% vs 3.5%, *p* = 0.0194). Quinolone-resistance isolates also presented higher prevalence to *bla*~CTX-M~ compared to quinolone-sensitive phenotype isolates (21% vs 5.2%, *p *= 0.012).

Discussion {#Sec16}
==========

In accordance with global trends, our results reveal higher prevalence of urinary tract infections in female patients than in males \[[@CR7], [@CR34]--[@CR36]\]. The emergence of high rates of antibiotic resistance and MDR-phenotype from urinary tract infections related bacteria becomes a public health concern worldwide. In this study, more than 70% of the isolates showed resistance to trimethoprim--sulfamethoxazole (TMP--SXT) that is recommended as a first choice for UTI treatment \[[@CR36]\]. Previous studies reported similar results \[[@CR20], [@CR36]\]. In agreement with Bouchillon et al. \[[@CR34]\] in this study, UPEC isolates presented more than 40% resistance to ciprofloxacin and levofloxacin antibiotics. Moreover, resistance rates to antimicrobial drugs were higher in isolates from male than in those from female patients \[[@CR37]\]. Interestingly, fluoroquinolones are widely used for the treatment of UTIs in male patients \[[@CR36], [@CR38]\]. It is possible that male infections may be more difficult to eradicate because of the higher rates of antibiotic resistance observed in strains isolated from males, which may lead to recurrent infections. These observations were similar to previous papers \[[@CR35], [@CR36], [@CR39]\]. Susceptibility analysis of isolates to antibiotics prior to treatment choice is recommended.

Multidrug-resistant strain prevalence (63.3%) was higher in this work than in other study from Mexico, which reported only 16.4% of MDR strains \[[@CR21]\]. While work of Paniagua-Contreras et al. \[[@CR20]\], showed 97% of MDR strains. It is well known that susceptibility patterns may vary in different geographical regions and can be change over time \[[@CR36]\]. In addition, an unexpected result was found, as the percentage of resistance to the antibiotics tested and MDR-phenotype were similar in hospital and community-acquired infections, indicating an important reservoir of resistance in both settings \[[@CR34]\]. This could be due to household use of antibiotics before 2010, which would were acquired without prescription then. Moreover, resistance to cephalosporin and nitrofurantoin was associated to hospital-acquired infections. Co-resistance with fluoroquinolones and TMP--SXT was also observed in both hospital and community.

As detected by Ochoa et al. \[[@CR21]\], phylo-group D, an important phylo-group in pathogenic ExPEC was associated to MDR-phenotype. Additionally, FQ-resistant strains were correlated to phylo-group D strains. Strains from hospital-acquired infections exhibited a greater number of virulence genes than those from community. In addition, *E. coli* isolates from hospital-acquired UTIs are correlated to the presence of *kpsMTII* gene that has been associated to pyelonephritis, a more severe infection of the upper urinary tract \[[@CR40]\]. In agreement with other studies \[[@CR20], [@CR41]\], our results showed an important frequency of *fyuA*-encoding yersiniabactin receptor and, *fimH* encoding type 1 fimbrial adhesion.

Detailed analysis of a strains subset using microarrays, revealed that some of them from both, hospital- and community-acquired infections carried virulence related genes of enteroaggregative and diffusely adherent *E*. *coli* (EAEC and DAEC), including *capU* (cap locus protein, hexosyltransferasa), *deoK* (deoxyribokinase), *shf* (putative virulence factor, plasmid pAA2, similar to *Shigella flexneri* Shf), *virK* (similar to *Shigella flexneri* virulence protein VirK, plasmid pAA2) and *astA* gene (EAEC heat-stable enterotoxin 1). This was also reported in previous works \[[@CR42]--[@CR45]\], which noticed that EAEC virulence related genes were among the most frequent markers of diarrheagenic *E*. *coli* reported in ExPEC strains. The *deoK* operon is frequently associated with strains isolated from infected urine and blood and is part of a large genetic island carrying genes contributing to the strain intrinsic virulence and/or adaptive properties \[[@CR43]\]. These strains, by acquiring the pAA plasmid, could become a potential diarrheal agent \[[@CR42]\].

Another finding was the presence of enteropathogenic *E*. *coli* (EPEC) related genes on five UPEC isolates. These genes included the *eae* (coding for intimin, a protein involved in attaching and effacing lesions), as well as virulence related genes such as *espG* (protein secreted by the type III secretion system and translocated into host epithelial cells), *eprJ* (*E*. *coli* type III secretion system 2 protein ErpJ), *epaS* (*E*. *coli* type III secretion system 2 protein EpaS), and *eivG* (*E*. *coli* type III secretion system 2 protein EivG) \[[@CR3], [@CR46]\]. T3SS genes are not common in UPEC isolates, however genes encoding components of T3SS have been found \[[@CR47], [@CR48]\]. These unusual gene combinations illustrate genome plasticity displayed by UPEC strains that may result in new hybrids pathotypes \[[@CR45], [@CR49], [@CR50]\].

In this study, UPEC strains carrying PMQR genes associated to quinolones resistance including *qnrA*, *qnrB*, *qnrS*, *qnrC* and *qnrD* as well as *aac(6′)*-*Ib*-*cr* were detected. The most common PMQR-genes identified were *qnrA* and *qnrB*, which is in contrast to previous studies were *aac(6′)*-*Ib*-*cr* gene detection was more frequent on ExPEC isolates \[[@CR19], [@CR51]\]. Moreover, *qnrA* and *qnrB* were frequently found as a part of MDR-phenotype. *qnrD* gene was found in 4.5% of the isolates. Previous papers reported *qnrD* in bacteria isolated from rooks \[[@CR51]\], pigs \[[@CR15]\] and humans clinical isolates of *Salmonella enterica* serovar Kentucky, serovar Bovismorbificans, *Proteus mirabilis* and *Morganella morganii* \[[@CR52], [@CR53]\], as well as in *E. coli* from dogs \[[@CR54]\]. In accordance to others studies \[[@CR19], [@CR55], [@CR56]\], *qepA* was not identified. Although PMQR genes provide a low level of FQ-resistance, they have been reported to favor the selection of additional chromosome-encoded resistance mechanism \[[@CR57]\]. In our study, QRDR mutations in *gyrA* and *parC* were prevalent in community-acquired infections (89% vs 11%). Overall, mutations in QRDR were equally present among isolates from males and females patients.

In our study, ESBL genes *bla*~CTX-M~ (*bla*~CTX-M-15~, *bla*~CTX-M-14~, *bla*~CTX-M-12~, and *bla*~CTX-M-3~), *bla*~TEM~, *bla*~PSE~, and *bla*~OXA~ were detected. For the isolates carrying resistance genes, ESBL genes such as TEM, SHV and CTX-M, are the most widespread and frequently detected in *E. coli* \[[@CR9]\]. In addition, CTX-M-15 is quite common in Mexico \[[@CR58], [@CR59]\].

Conclusions {#Sec17}
===========

Our study describes significant antimicrobial resistance in *E*. *coli* UTI isolates from hospital and community in Mexico. Diverse genotypes and phenotypes including multidrug-resistance, fluoroquinolone resistance and carriage of virulence genes related to several enteropathogenic *E. coli* were found among UPEC isolates. Thus, continuous surveillance for antimicrobial resistance of UPEC is needed in order to prevent treatment failure and to improve the strategies to mitigate the occurrence of antibiotic resistance organisms and ensure the best treatment to UTI patients. This study highlights the importance of antimicrobial resistance of virulent *E. coli* from urinary tract infection in Mexico.

UTIs

:   urinary tract infections

MDR

:   multiple drug resistance

ExPEC

:   extra-intestinal pathogenic *E. coli*

ESBL

:   extended-spectrum beta-lactamase

QRQR

:   quinolone resistance-determining region

FQ-phenotype

:   fluoroquinolone resistance phenotype
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